GlassScriptPhysician profile
Andrew M Eisele
NPI 1497380414
$1,292.97
in general payments reported to CMS, 2019-2025
15 companies · $17.88 in 2025
The $17.88 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2023: $425 · 2024: $518 · 2025: $17.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $504.97 | 2021-2024 | Neurostar Tms Therapy System |
| Abbvie INC. | $238.86 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $75.97 | 2021-2023 | Rexulti |
| Corium, LLC | $73.62 | 2023 | Azstarys |
| Alkermes, INC. | $53.55 | 2021-2024 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $53.45 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.43 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $52.10 | 2021-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $40.77 | 2023 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $40.44 | 2021 | |
| Neurocrine Biosciences, INC. | $34.68 | 2023 | Ingrezza |
| Axsome Therapeutics, INC. | $21.53 | 2023 | Auvelity |
| Lundbeck LLC | $18.54 | 2023 | Rexulti |
| Boston Scientific Corporation | $17.88 | 2025 | Watchman Flx |
| Idorsia Pharmaceuticals US INC | $13.18 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Eisele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.